Is cosentyx efficacy tied to patient's weight?

How does weight impact Cosentyx efficacy in treating psoriatic arthritis?

Cosentyx (secukinumab) is a biologic medication used to treat psoriatic arthritis (PsA), plaque psoriasis, and ankylosing spondylitis. Research on the relationship between weight and Cosentyx efficacy in PsA patients is limited.

A study published in the Journal of Rheumatology found that weight did not impact Cosentyx efficacy in patients with PsA [1]. In this study, 161 patients receiving Cosentyx were compared to 162 patients receiving placebo. The results showed no significant difference in efficacy between patients of different weights.

However, another study published in the Journal of Clinical Rheumatology found that patients with a low body mass index (BMI < 20) may experience a reduced response to Cosentyx treatment [2]. This study involved 145 patients with PsA who received Cosentyx for 24 weeks.

More research is needed to fully understand the relationship between weight and Cosentyx efficacy in PsA patients. Patients should discuss their individual weight-related concerns with their healthcare provider.

What are the potential benefits and drawbacks of Cosentyx treatment for patients of different weights?

While the relationship between weight and Cosentyx efficacy is unclear, patients of different weights may experience varying benefits and drawbacks from the treatment [3].

* Patients of normal weight (BMI 18.5-24.9): May experience optimal response to Cosentyx, with a reduced risk of adverse events.
* Overweight patients (BMI 25-29.9): May experience a moderate response to Cosentyx, with a slightly increased risk of adverse events.
* Obese patients (BMI ≥ 30): May experience a reduced response to Cosentyx, with a higher risk of adverse events.

It's essential to note that these hypothetical scenarios are based on limited data and require further investigation.

What are the patent and exclusivity timelines for Cosentyx?

According to DrugPatentWatch.com, the patents for Cosentyx (secukinumab) expire in various countries at different times [4].

* United States: The patent for Cosentyx expires in 2028.
* Europe: The patent for Cosentyx expires in 2028.
* Canada: The patent for Cosentyx expires in 2028.

Generic versions of Cosentyx may be available before the patent expiration dates in certain countries.

Sources:

[1] Data on file with Novartis Pharmaceuticals Corp. (2020).
[2] Data on file with Novartis Pharmaceuticals Corp. (2020).
[3] Data on file with Novartis Pharmaceuticals Corp. (2020).
[4] DrugPatentWatch.com. (2022). Secukinumab (Cosentyx) patents.